Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Raleigh, NC
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Beachwood, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Beachwood, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Columbus, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Gahanna, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Gahanna, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
South Euclid, OH
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
South Euclid, OH
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Portland, OR
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Mt. Pleasant, SC
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Austin, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Dallas, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
San Antonio, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
West Jordan, UT
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Norfolk, VA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Roanoke, VA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Seattle, WA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
Status: Enrolling
Updated:  7/27/2015
GSK Investigational Site
mi
from
Baltimore, MD
A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
Status: Enrolling
Updated: 7/27/2015
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
mi
from
Birmingham, AL
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Little Rock, AR
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Pasadena, CA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
San Diego, CA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Newnan, GA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Newnan, GA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Snellville, GA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Snellville, GA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Champaign, IL
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Champaign, IL
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigational Site
mi
from
Springfield, IL
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
mi
from
Evansville, IN
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
mi
from
Topeka, KA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
mi
from
Topeka, KA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Louisville, KY
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative site
mi
from
Boston, MA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Clinton Twp., MI
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Clinton Twp., MI
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Detroit, MI
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigator Site
mi
from
Minneapolis, MN
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
St. Louis, MO
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Omaha, NE
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Henderson, NV
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Henderson, NV
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis
mi
from
New York, NY
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Rochester, NY
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
High Point, NC
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigational Site
mi
from
Lake Oswego, OR
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigational Site
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis
mi
from
Portland, OR
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Philadelphia, PA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigational Site
mi
from
Austin, TX
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative site
mi
from
Dallas, TX
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Charlottesville, VA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Lynchburg, VA
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Lynchburg, VA
Click here to add this to my saved trials
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  7/30/2015
Novartis Investigative Site
mi
from
Nice,
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 7/30/2015
Novartis Investigative Site
mi
from
Nice,
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
mi
from
San Diego, CA
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
mi
from
St Louis, MO
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated:  8/6/2015
Clinical Research Facility
mi
from
Houston, TX
Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Status: Enrolling
Updated: 8/6/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials